Recent advances: personalised use of current Crohn's disease therapeutic options

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays

(2012) N. Vande Casteele et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

(2012) Shomron Ben–Horin et al.   Clinical Gastroenterology and Hepatology

Factors affecting outcomes in Crohn's disease over 15 years

(2012) Jacques Cosnes et al.   GUT

Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response

(2012) Lior Katz et al.   INFLAMMATORY BOWEL DISEASES

The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic

(2012) M. Smith et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial

(2012) N. Vande Casteele et al.   Journal of Crohns & Colitis

Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis

(2011) James C. Lee et al.   JOURNAL OF CLINICAL INVESTIGATION

Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study

(2011) Jean-Camille Méric et al.   THERAPEUTIC DRUG MONITORING

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort

(2010) Kelvin T. Thia et al.   GASTROENTEROLOGY

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

(2010) A. Dignass et al.   Journal of Crohns & Colitis

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

(2010) Matthieu Allez et al.   Journal of Crohns & Colitis

A CD8+ T cell transcription signature predicts prognosis in autoimmune disease

(2010) Eoin F McKinney et al.   NATURE MEDICINE

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis

(2009) I. Arijs et al.   GUT

Serum anti-glycan antibodies predict complicated Crohnʼs disease behavior

(2009) Florian Rieder et al.   INFLAMMATORY BOWEL DISEASES

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

(2009) Ann K Daly et al.   NATURE GENETICS

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Perianal Disease Predicts Changes in Crohn's Disease Phenotype-Results of a Population-Based Study of Inflammatory Bowel Disease Phenotype

(2008) Kelly M. Tarrant et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Gene expression signature for recurrence in stage III colorectal cancers

(2008) Toshiaki Watanabe et al.   CANCER

Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort

(2008) R K Weersma et al.   GUT

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of severe Crohn's disease

(2008) Catherine Loly et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY